Key Reason Some Cancer Patients Relapse After Receiving CAR-T Cell Therapy – Mayo Clinic
Cheryl Willman, Enterprise Executive Director of Mayo Clinic Comprehensive Cancer Center, shared a post by Mayo Clinic, adding:
“Congratulations to Mayo Clinic’s Dr Saad Sirop Kenderian and his team at Mayo Clinic Comprehensive Cancer Center – including Dr Ismail Can supported by the 5th District Eagles Cancer Telethon – for their critical discovery explaining why certain patients relapse after CAR-T cell therapy due to cellular senescence. A pathway that can be reversed to enhance the effectiveness of CAR-T cells. Thank you to Michael and Georgia Michelson for their critical support to Cure CLL.”
Quoting Mayo Clinic‘s post:
“Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune cells age and lose their ability to fight cancer.
Published in Molecular Cancer, the study identifies this aging process, known as senescence, as a previously unrecognized mechanism of CAR-T failure. Learn more.”
More posts featuring Mayo Clinic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023